Cathay Biotech (688065) Zheng Quan Zhi Xing·2025-04-02 14:14Core Viewpoint - Shanghai Kasei Biotechnology Co., Ltd. has completed the issuance of A-shares to a specific entity, Shanghai Yaoxiu Biotechnology Partnership, raising approximately RMB 5.93 billion through the issuance of 137,911,755 shares at a price of RMB 42.97 per share [1][2][3] Summary by Sections Issuance Details - The company issued 137,911,755 A-shares at a par value of RMB 1.00 per share, with a total subscription amount of RMB 5,926,068,112.35 [1][3] - The issuance has been registered and completed with the China Securities Depository and Clearing Corporation [1][3] Control and Ownership Changes - The actual controller of the company remains the Liu Xiucai family, despite the change in the controlling shareholder from CIB to Shanghai Yaoxiu [2][6][8] - Before the issuance, CIB held 28.32% of the shares, which will decrease to 6.73% post-issuance, while Shanghai Yaoxiu will hold 35.29% [4][6][8] - The Liu Xiucai family controlled a total of 30.82% of the voting rights before the issuance, which will increase to 44.04% after the issuance [6][8] Regulatory Approvals - The issuance plan has been approved by multiple board meetings and shareholder meetings, ensuring compliance with relevant regulations [2][3] - The registration approval for the issuance is valid for 12 months, expiring on November 25, 2024 [3][5] Transaction Completion - The share transfer from CIB to Shanghai Yaoxiu, involving 116,655,640 shares, has been completed, with the transfer date recorded as December 31, 2024 [7][8] - The company has disclosed the completion of the share transfer and the change in controlling shareholder on January 3, 2025 [7][8]